Employees: 626
Size Ningbo Jansen Superconducting Technologies (688805.SS) is a China Health Care company (Medical Specialties) with a market value of $818M, the 2544th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥33.20 on 18 Nov 2026.
Performance Over six months the shares fell 35.9%, against -12.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 35.6% over the last twelve months (peer median +6.2%); the operating margin is 15.9% (peer median 9.4%).
Valuation It trades at 6.8× enterprise value to sales against a peer median of 3.5× (7th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.1 points above its cost of capital (12.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥720M | CN¥577M | CN¥425M | CN¥451M | CN¥359M |
| Revenue growth | — | +36% | -6% | +26% | — |
| Gross profit | CN¥214M | CN¥150M | CN¥107M | CN¥110M | CN¥74.6M |
| EBITDA | n/a | CN¥98.7M | CN¥71.5M | CN¥62.1M | CN¥48.6M |
| Net income | CN¥108M | CN¥75.1M | CN¥55.8M | CN¥48.7M | CN¥34.6M |
| Free cash flow | n/a | CN¥20.0M | -CN¥43.8M | CN¥33.1M | -CN¥51.0M |
| Capital expenditure | n/a | CN¥24.0M | CN¥23.2M | CN¥36.7M | CN¥14.3M |
| Total debt | CN¥123M | CN¥78.8M | CN¥76.6M | CN¥105M | CN¥59.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688805.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.2% | -4.8% | 10th lowest of 21 |
| 6-month return | -35.9% | -12.6% | 4th lowest of 21 |
| Distance from 52-week high | -54.3% | -37.6% | 6th lowest of 21 |
| Revenue growth (TTM) | +35.6% | +6.2% | 5th highest of 21 |
| Operating margin | 15.9% | 9.4% | 4th highest of 21 |
| EV / Sales | 6.8× | 3.5× | 7th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 35.6% | 6.7% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +17.1% | +11.8% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | +18.4 pp | -3.7 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | +2.1 pp | -1.9 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | 3.4× | n/a | n/a |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 1.0× | -6.4% | +6.6% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 0.7× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 1.6× | -7.1% | +11.3% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | 7.7× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | 12.0× | 11.1% | +4.6% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 13.7× | 37.6% | +12.4% |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 3.3× | 16.8% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 1.2× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 3.6× | 3.8% | +105.8% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | 21.7× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 7.2× | n/a | n/a |